Cystatin C and kidney injury after cardiac surgery

Cardiac surgery places the kidneys under substantial physiological stress. During cardiopulmonary bypass, shifts in perfusion, inflammation and fluid balance can reduce glomerular filtration. Injury that starts in theatre may become obvious only in the intensive care unit, so clinicians need tools that reveal loss of renal reserve early and distinguish transient dysfunction from established acute kidney injury.

Cystatin C is a small protein produced by nucleated cells and filtered by the kidneys. Because it is less dependent on muscle mass than serum creatinine, it can provide useful information when creatinine is distorted by frailty, fluid shifts or low muscle mass. Used as a baseline and serial measurement, it may improve risk stratification and complement—not replace—creatinine, urine output and haemodynamic assessment.

The role of Cystatin C in predicting acute kidney injury after cardiac surgery is therefore clinically important but frequently overstated. Its best use is within a structured pathway that combines biomarker results with surgical complexity, perfusion and medication exposure. Current evidence, important uncertainties and practical approaches for Australian teams are examined below.

Why prediction matters after cardiac surgery

Acute kidney injury after cardiac surgery is common enough to matter, especially after emergency procedures, prolonged bypass, haemodynamic instability, transfusion or sepsis. Even a modest creatinine rise can be associated with longer ventilation, dialysis, prolonged hospital stay and higher later mortality. A predictive marker is valuable when it changes surveillance and prevention before injury becomes severe.

Current KDIGO staging remains creatinine-based and includes a rise of at least 26.5 µmol/L within 48 hours or 1.5-fold above baseline within seven days, together with criteria based on urine output. Cystatin C does not replace this framework. Its principal value is to help anticipate declining filtration and identify patients who may need closer renal monitoring.

Creatinine has practical value but rises after a renal insult. In low-flow states, it can lag behind falling filtration, and a stable early result does not guarantee normal function. Fluid overload may dilute creatinine and obscure deterioration. Conversely, low muscle mass can make a modest elevation look more alarming than it is, while aggressive fluid administration can delay recognition.

Risk scores using creatinine, age, comorbidities and procedure type estimate broad postoperative risk but often miss dynamic changes. Serial laboratory markers may add information about the kidney’s response to bypass and the adequacy of perfusion. The clinical goal is an early, repeatable signal that prompts review of oxygen delivery, volume status, nephrotoxic medicines and renal monitoring.

What cystatin C adds to creatinine

Cystatin C is produced at a relatively stable rate and freely filtered, with only limited tubular reabsorption. This makes its concentration attractive as an estimate of glomerular filtration. Many laboratories can measure it by immunoassay, and combined creatinine–cystatin C equations often classify chronic kidney disease more accurately than creatinine alone, particularly in people with low muscle mass.

The perioperative setting is less straightforward. Cystatin C can rise with systemic inflammation, glucocorticoid use, thyroid disease, obesity and smoking, while fluid shifts and changes in clearance affect any concentration. A postoperative result is useful mainly as part of a trajectory: a stable baseline, a rise after surgery and a subsequent fall suggest different processes from a high value present before theatre. Timing must be aligned with the clinical course.

For patients with pre-existing kidney disease, trends may matter more than a single threshold. The journal’s wider coverage of open and laparoscopic approaches offers a useful parallel: preserving renal tissue and documenting postoperative function are related goals, yet they require different measures and time points. Cystatin C should complement assessments of haemodynamics, urine output and chronic disease rather than serve as a stand-alone renal diagnosis.

How well does it predict in practice

Studies of cystatin C after cardiac surgery generally support its value as an early marker of reduced filtration, but reported performance varies with patient selection, surgery type, sampling times and definitions of acute kidney injury. Some cohorts show stronger prediction than others, and many are observational. A marker can predict a poor outcome for a group without identifying with certainty which individual patient will be affected.

Several factors complicate interpretation. Critical illness, inflammation, steroids, thyroid status, age, obesity and smoking can alter cystatin C independently of filtration. Acute kidney injury also breaks the steady-state assumptions underlying estimated glomerular filtration rate equations. Combined creatinine–cystatin C formulae are useful for chronic risk classification, but their precision during the first postoperative hours or days is less certain.

No universal postoperative cut-off should dictate treatment. Decisions need a local reference range, assay information, the patient’s baseline and a clear account of clinical events. This approach also applies to long-term urological recovery, where issues described in pelvic fracture recovery involve anatomy, continence and renal outcomes together. Follow-up must extend beyond hospital discharge when kidney function remains unsettled.

Fitting prediction into Australian care

Australian hospitals mix public and private pathways. Medicare covers much public hospital care, while private health insurance and outpatient arrangements affect who pays for additional pathology. Coverage for cystatin C testing can depend on the MBS schedule, local ordering rules and the patient’s setting, so clinicians should verify current reimbursement rather than promise a test is routinely funded. Pathology turnaround and assay availability also vary between laboratories.

Cardiac surgery is concentrated in tertiary centres in Melbourne, Sydney, Brisbane and Perth, while many patients arrive from regional and rural areas. A practical pathway must account for transfer, discharge planning and repeated blood tests after patients return home. In Australian hospital shorthand, a “post-op” cystatin C trend can prompt review by the ICU, cardiology and renal teams, but ownership should be explicit rather than assumed.

Patient information should state which result is concerning, what the team will do and whom to contact. Geographic assumptions in international material can mislead people navigating Medicare, specialist referrals or local follow-up; an overseas community portal such as Brooks County resources should always be checked against its jurisdiction. Australian patients should prioritise their treating service, Healthdirect and local general practitioners for locally applicable advice.

Practical recommendations for perioperative kidney care

A sensible strategy is to standardise when cystatin C is ordered, how it is interpreted and who acts. The marker is most useful when embedded in a perioperative kidney-protection bundle. General family resources can support relatives managing recovery at home, but they cannot replace discharge advice or the treating team’s interpretation of postoperative renal results.

Before changing practice, a service should review its baseline data, assay characteristics and current definitions of acute kidney injury. This creates a transparent standard and reduces inconsistent thresholds.

• Record baseline serum creatinine, eGFR and cystatin C when feasible before surgery, especially in people with chronic kidney disease, diabetes, frailty or complex disease.
• Define sampling times relative to cardiopulmonary bypass, ICU admission and postoperative days so trends remain comparable.
• Interpret serial changes alongside haemodynamics, urine output, fluid balance, sepsis and nephrotoxin exposure.
• Use combined creatinine–cystatin C eGFR cautiously during acute non-steady-state periods and retain the laboratory’s validated reporting method.
• Avoid treating a single elevated cystatin C value as a stand-alone indication for dialysis, diuretics or contrast administration.
• Establish follow-up for persistent abnormalities and document a renal plan before discharge from metropolitan or regional centres.

Clinical services ready to act should begin with a measurable project: map one cardiac surgery pathway, compare baseline and postoperative testing, select the responsible team and review outcomes after three months. Urologists, nephrologists, intensive care specialists, cardiac surgeons and laboratory staff can use the available evidence and local data to build a shared protocol. Start before the next service meeting, with one result, one action threshold and one follow-up owner clearly assigned.